Basic HTML Version
28
JOHN DANIEL HOLDINGS LIMITED AND ITS SUBSIDIARIES
INTEGRATED ANNUAL REPORT 2011
Lazaron Biotechnologies (SA) Ltd established its leader-
ship in this field as the first company to store cord blood
stem cells in South Africa. The company was founded in
2005 after the development of our technology at the Stel-
lenbosch University by well-known stem cell researcher,
Dr Daniel Barry, and his research team. The company cur-
rently has in excess of 600 shareholders.
The primary aim of the company is to develop stem cell
related Biotechnology, leveraging health enhancing
knowledge and products. This technology is based on
the careful and ethical use of adult stem cells. The com-
pany ensures that it is at the forefront of worldwide de-
velopment in the field through collaboration with inter-
national companies/consortiums, such as Cryo-Save NV
and the Asian Pacific Cord Blood Bank Consortium.
Cord Blood Stem Cells
Cord blood is generally defined as blood contained
within the umbilical cord and contiguous placental cir-
culation. These stem cells help the embryo develop into
a fully grown baby. As the baby develops, the umbilical
cord and the populating red blood cells also grow and
multiply to provide it with nutrition and oxygen.
Cord stem cells can be harvested from the umbilical cord
of new-born babies without any risk to mother or infant,
and it is a painless procedure. The number of stem cells
available for storage relates directly to the volume of
cord blood that is collected after birth.
The cells can only be collected for a limited period im-
mediately after birth and the non-invasive procedure
takes the health care professional around five minutes
Saving a lifeline for the future
Lazaron Biotechnologies (SA) Ltd